Forest Laboratories Announces Positive Phase III Study Results For Nebivolol And Valsartan Combination In Hypertension

Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from an 8-week pivotal Phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.

The combination of nebivolol and valsartan demonstrated statistically significant reductions in diastolic blood pressure (DBP) vs. both nebivolol alone and valsartan alone at 8 weeks , which was the primary endpoint. The FDC also met the key secondary endpoint of change from baseline in systolic blood pressure (SBP) at 8 weeks.

The single pivotal nebivolol/valsartan FDC trial was designed to meet the required regulatory “Combination Rule,” comparing a FDC against the highest approved dose of each component drug.

“These Phase III results in patients with Stage 1 or Stage 2 hypertension are exciting and demonstrate the potential benefits of this novel FDC -- a first-in-class beta blocker/ARB combination,” said Marco Taglietti, MD, Senior Vice President of Research and Development and President, Forest Research Institute. “We are very pleased with these results which demonstrate the efficacy and safety profile of this combination and support the potential use of the nebivolol/valsartan FDC as a new treatment option for patients with hypertension who need dual therapy to reach their blood pressure goals.”

Based on these positive results, Forest plans to submit a regulatory filing with the Food and Drug Administration (FDA) in the first quarter of calendar year 2014.

About the Phase III Study

This pivotal 8-week randomized, double-blind, placebo-controlled clinical trial in 4,161 hypertension patients studied nebivolol 5, 10, 20, and 40mg and valsartan 80, 160, and 320mg alone and in fixed dose combinations.

The study consisted of a 1-week screening period, followed by 6 weeks of placebo wash-out, an 8-week double-blind treatment period, and a 1-week down-titration period. During the double-blind treatment period, patients were initially randomized to one of eight treatment groups: FDC nebivolol/valsartan 5/80, 5/160, or 10/160mg; nebivolol 5 or 20mg; valsartan 80 or 160mg or placebo. After four weeks, all dosages were doubled.

If you liked this article you might like

Cramer: There Are Some Bargains Out There

Cramer: There Are Some Bargains Out There

Teva, Actavis, Other Generic Drugmakers May Be on Acquisition Trail

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Why Endo International Can Deliver Solid Rewards With Minimal Risk

3 Stocks Driving The Health Care Sector Higher